Please login to the form below

Not currently logged in

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients
Janssen Logo

Janssen has launched Stelara in the UK as a treatment option for adolescents with moderate-severe plaque psoriasis.

The launch follows the European Commission's approval of Stelara (ustekinumab) in June this year, which was based on data from the phase III CADMUS trial.

This showed that after 12 weeks patients aged 12 to 17 years treated with Stelara had much greater improvement in their psoriasis compared to those on placebo.

Dr Rozlyn Bekker, medical director at Janssen UK, said: “The CADMUS study has shown that ustekinumab is an efficacious treatment option that can significantly improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over.”

Stelara is an interleukin (IL)-12 and IL-23 antagonist and is approved for those who have not responded to other systematic therapies such as ciclosporin, methotrexate or psoralen plus ultraviolet A (PUVA).

Dr Anthony Bewley of Royal London Hospital, said: “Ustekinumab is an innovative biologic which, we know from recent trials, can positive impact the lives of younger people with psoriasis.“

Ustekinumab has been used in adults for a number of years and we know it has been beneficial in the management of adult psoriasis, so to have the full data for the use of this medication in younger people is a great step forward.”

Plaque psoriasis is a chronic autoimmune disease affecting up to 2% of the population during childhood and adolescence equating to around 40,000 children.

It is characterised by patches of thick, red or inflamed skin covered with plaques.  

Article by
Nikhil Patel

15th September 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...